These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

70 related articles for article (PubMed ID: 9464099)

  • 21. Continuum of renoprotection with losartan at all stages of type 2 diabetic nephropathy: a post hoc analysis of the RENAAL trial results.
    Remuzzi G; Ruggenenti P; Perna A; Dimitrov BD; de Zeeuw D; Hille DA; Shahinfar S; Carides GW; Brenner BM;
    J Am Soc Nephrol; 2004 Dec; 15(12):3117-25. PubMed ID: 15579515
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [The safety of long-term administration of losartan in current clinical practice: a non-intervention NCT-CZ 14/04/LOZ study].
    Krupicka J; Ceypová K; Kristenová P; Hauser T
    Vnitr Lek; 2008 Nov; 54(11):1031-8. PubMed ID: 19069675
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Losartan-induced hepatotoxicity.
    Bosch X
    JAMA; 1997 Nov; 278(19):1572. PubMed ID: 9370501
    [No Abstract]   [Full Text] [Related]  

  • 24. Long-term antiproteinuric and renoprotective efficacy and safety of losartan in children with proteinuria.
    Ellis D; Vats A; Moritz ML; Reitz S; Grosso MJ; Janosky JE
    J Pediatr; 2003 Jul; 143(1):89-97. PubMed ID: 12915830
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Better prognosis in hypertension and left ventricular hypertrophy. LIFE Study sets new standard].
    MMW Fortschr Med; 2002 May; 144(20):60-1. PubMed ID: 12119887
    [No Abstract]   [Full Text] [Related]  

  • 26. Anemia due to losartan in hypertensive renal transplant recipients without posttransplant erythrocytosis.
    Ersoy A; Kahvecioglu S; Ersoy C; Cift A; Dilek K
    Transplant Proc; 2005 Jun; 37(5):2148-50. PubMed ID: 15964363
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hereditary angioedema type III, angioedema associated with angiotensin II receptor antagonists, and female sex.
    Bork K; Dewald G
    Am J Med; 2004 May; 116(9):644-5. PubMed ID: 15093766
    [No Abstract]   [Full Text] [Related]  

  • 28. [Angioedema-urticaria caused by angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists].
    de Paz S; Martín AB; Iglesias A; Domínguez AR
    Med Clin (Barc); 1999 Dec; 113(19):759. PubMed ID: 10680137
    [No Abstract]   [Full Text] [Related]  

  • 29. Comparative evaluation of the antihypertensive activities of losartan and HM70186 during liver dysfunction.
    Lee S
    Arch Pharm Res; 2009 Jul; 32(7):965-6. PubMed ID: 19641875
    [No Abstract]   [Full Text] [Related]  

  • 30. Antihypertensive and renoprotective efficacy and safety of losartan. A long-term study in children with renal disorders.
    Ellis D; Moritz ML; Vats A; Janosky JE
    Am J Hypertens; 2004 Oct; 17(10):928-35. PubMed ID: 15485756
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [What are the consequences of the LIFE Study for general practice].
    Zidek W
    MMW Fortschr Med; 2002 Sep; 144(38):48. PubMed ID: 12395704
    [No Abstract]   [Full Text] [Related]  

  • 32. Renoprotection of Optimal Antiproteinuric Doses (ROAD) Study: a randomized controlled study of benazepril and losartan in chronic renal insufficiency.
    Hou FF; Xie D; Zhang X; Chen PY; Zhang WR; Liang M; Guo ZJ; Jiang JP
    J Am Soc Nephrol; 2007 Jun; 18(6):1889-98. PubMed ID: 17494885
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of atenolol and losartan on baroreflex sensitivity and heart rate variability in uncomplicated essential hypertension.
    Chern CM; Hsu HY; Hu HH; Chen YY; Hsu LC; Chao AC
    J Cardiovasc Pharmacol; 2006 Feb; 47(2):169-74. PubMed ID: 16495752
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical experience in treating hypertension with fixed-dose combination therapy: angiotensin II receptor blocker losartan plus hydrochlorothiazide.
    Abe M; Okada K; Matsumoto K
    Expert Opin Drug Metab Toxicol; 2009 Oct; 5(10):1285-303. PubMed ID: 19761411
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Angioedema due to losartan.
    Rupprecht R; Vente C; Gräfe A; Fuchs T
    Allergy; 1999 Jan; 54(1):81-2. PubMed ID: 10195365
    [No Abstract]   [Full Text] [Related]  

  • 36. The effect of losartan and losartan/hydrochlorothiazide fixed-combination on magnesium, zinc, and nitric oxide metabolism in hypertensive patients: a prospective open-label study.
    Koren-Michowitz M; Dishy V; Zaidenstein R; Yona O; Berman S; Weissgarten J; Golik A
    Am J Hypertens; 2005 Mar; 18(3):358-63. PubMed ID: 15797654
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hepatic injury associated with losartan.
    Andrade RJ; Lucena MI; Santalla F
    Ann Pharmacother; 1998 Dec; 32(12):1371. PubMed ID: 9876824
    [No Abstract]   [Full Text] [Related]  

  • 38. [German Hypertension League on the LIFE Study. New evaluation of AT1 receptor antagonists].
    Dominiak P; Zidek W
    MMW Fortschr Med; 2002 Sep; 144(38):47. PubMed ID: 12395703
    [No Abstract]   [Full Text] [Related]  

  • 39. A comparative evaluation of therapeutic effects of once a day dose of losartan potassium versus enalapril maleate in mild to moderate essential hypertension.
    Neki NS; Arora P
    J Indian Med Assoc; 2001 Nov; 99(11):640-1. PubMed ID: 12022207
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Reversible dysgeusia attributed to losartan.
    Heeringa M; van Puijenbroek EP
    Ann Intern Med; 1998 Jul; 129(1):72. PubMed ID: 9653007
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.